What is the 13F Pro Quality Score for FOLD?

13F Pro ranks AMICUS THERAPEUTICS, INC. (FOLD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FOLD's current score at https://13fpro.ai/company/FOLD (free sign-up required for the full ranking).

Which hedge funds own the most FOLD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of FOLD include BlackRock,, UBS Group AG, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/FOLD as soon as new 13F filings post.

Where does 13F Pro source FOLD data?

All AMICUS THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. AMICUS THERAPEUTICS, INC. files with the SEC under CIK 1178879. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FOLD in?

AMICUS THERAPEUTICS, INC. (FOLD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FOLD research updated on 13F Pro?

FOLD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AMICUS THERAPEUTICS, INC.(FOLD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1178879 FOLD stock profile & AI dashboard →

13F Pro Quality Score

47.4/100

Rank #1,782 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

85.2/100

Profitability

36.5/100

Balance Sheet

25.5/100

Earnings Quality

67.2/100

Free Cash Flow

41.3/100

Institutional Flow

2.2/100

Revenue Scale

41.2/100

Dilution Risk

12.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why FOLD Scores 48/100

exact factor attribution · 2026-08-29

FOLD's composite is driven by revenue growth and earnings quality, held back by institutional flow and capital efficiency. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.8 pts

89th pct

Earnings quality

+1.7 pts

67th pct

Scale

-0.8 pts

45th pct

Earnings growth

-1.0 pts

30th pct

Free cash flow

-1.5 pts

40th pct

Shareholder dilution

-1.9 pts

13th pct

Profitability

-2.1 pts

36th pct

Capital efficiency

-2.3 pts

27th pct

Institutional flow

-2.4 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

FOLD Stock Analysis & AI Quality Score

Data updated 2026-08-29

AI stock analysis and institutional research for AMICUS THERAPEUTICS, INC. (FOLD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FOLD at 47.4/100 on a 32-signal composite quality model, placing it at rank #1,782 of 2,962 stocks — the bottom half of the AI-ranked universe. FOLD scores in the top quartile across revenue growth (85.2). Areas of concern include institutional flow (2.2) and balance sheet strength (25.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), AMICUS THERAPEUTICS, INC. reports quarterly revenue of $185.2M, net income of $1.7M, an operating margin of 8.6%. Top institutional holders of FOLD by reported 13-F value include BlackRock, UBS Group AG, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. FOLD trades on the Nasdaq exchange and files with the SEC under CIK 1178879. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FOLD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AMICUS THERAPEUTICS, INC. directly from SEC EDGAR. AMICUS THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 22 and 51 since 2021, currently 47.4 — an improving long-term trajectory across 67 quarterly and live scoring snapshots.

Revenue

Q4 2025

$185.2M

Net Income

Q4 2025

$1.7M

Free Cash Flow

Q4 2025

$16.0M

Operating Margin

Q4 2025

8.6%

ROIC

Q4 2025

9.6%

D/E Ratio

Q4 2025

1.43

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+20.0% YoY

$634.2MFY 2025

FY22 $329.2MFY23 $399.4MFY24 $528.3MFY25 $634.2M

Net Income

+51.7% YoY

$-27.1MFY 2025

FY22 $-236.6MFY23 $-151.6MFY24 $-56.1MFY25 $-27.1M

Operating Income

+31.8% YoY

$32.8MFY 2025

FY22 $-212.1MFY23 $-77.2MFY24 $24.9MFY25 $32.8M

EPS (Diluted)

+50.0% YoY

$-0.09FY 2025

FY22 $-0.82FY23 $-0.51FY24 $-0.18FY25 $-0.09

Total Assets

+21.0% YoY

$949.9MFY 2025

FY22 $724.2MFY23 $777.9MFY24 $785.0MFY25 $949.9M

Total Debt

+0.7% YoY

$392.7MFY 2025

FY22 $392.0MFY23 $387.9MFY24 $390.1MFY25 $392.7M

Op. Cash Flow

+197.8% YoY

$33.1MFY 2025

FY22 $-166.6MFY23 $-69.1MFY24 $-33.9MFY25 $33.1M

Free Cash Flow

+179.7% YoY

$29.8MFY 2025

FY22 $-170.3MFY23 $-76.5MFY24 $-37.4MFY25 $29.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$634.2M +20.0%	$528.3M +32.3%	$399.4M +21.3%	$329.2M +7.8%	$305.5M +17.1%	$260.9M
Net Income	$-27.1M +51.7%	$-56.1M +63.0%	$-151.6M +35.9%	$-236.6M +5.5%	$-250.5M +9.5%	$-276.9M
Operating Income	$32.8M +31.8%	$24.9M +132.2%	$-77.2M +63.6%	$-212.1M -2.8%	$-206.4M +16.4%	$-247.0M
EPS (Diluted)	$-0.09 +50.0%	$-0.18 +64.7%	$-0.51 +37.8%	$-0.82 +10.9%	$-0.92 +14.0%	$-1.07
Total Assets	$949.9M +21.0%	$785.0M +0.9%	$777.9M +7.4%	$724.2M -20.0%	$905.1M +2.1%	$886.5M
Total Debt	$392.7M +0.7%	$390.1M +0.6%	$387.9M -1.1%	$392.0M +0.7%	$389.4M +0.0%	$389.3M
Operating Cash Flow	$33.1M +197.8%	$-33.9M +50.9%	$-69.1M +58.5%	$-166.6M +17.7%	$-202.5M +13.2%	$-233.3M
Free Cash Flow	$29.8M +179.7%	$-37.4M +51.1%	$-76.5M +55.1%	$-170.3M +17.5%	$-206.4M +12.7%	$-236.5M

Get alerted when FOLD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AMICUS THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FOLD

BlackRock, Inc.
$489.9M33,879,048 sh
UBS Group AG
$230.8M15,957,913 sh
VANGUARD CAPITAL MANAGEMENT LLC
$202.8M14,023,557 sh
Pentwater Capital Management LP
$202.4M14,000,000 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$202.1M13,974,932 sh
STATE STREET CORP
$186.4M12,893,897 sh
FIL Ltd
$181.6M12,560,028 sh
GOLDMAN SACHS GROUP INC
$167.1M11,556,008 sh
Qube Research & Technologies Ltd
$127.4M8,809,340 sh
HBK INVESTMENTS L P
$127.0M8,783,448 sh

Fund	Value	Shares
BlackRock, Inc.	$489.9M	33,879,048
UBS Group AG	$230.8M	15,957,913
VANGUARD CAPITAL MANAGEMENT LLC	$202.8M	14,023,557
Pentwater Capital Management LP	$202.4M	14,000,000
VANGUARD PORTFOLIO MANAGEMENT LLC	$202.1M	13,974,932
STATE STREET CORP	$186.4M	12,893,897
FIL Ltd	$181.6M	12,560,028
GOLDMAN SACHS GROUP INC	$167.1M	11,556,008
Qube Research & Technologies Ltd	$127.4M	8,809,340
HBK INVESTMENTS L P	$127.0M	8,783,448

Companies Similar to FOLD

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CWAN

Clearwater Analytics Holdings, Inc.

AI score

Very similar · 2 shared holders

KRYGER CAPITAL Ltd CIBRA Capital Ltd

ACLX

Arcellx, Inc.

AI score

Shared smart-money ownership · 2 shared holders

CIBRA Capital Ltd Abich Financial Wealth Management LLC

APLS

Apellis Pharmaceuticals, Inc.

AI score

Shared smart-money ownership · 2 shared holders

CIBRA Capital Ltd Point72 Hong Kong Ltd

MASI

MASIMO CORP

AI score

Similar quality profile · 1 shared holders

CIBRA Capital Ltd

HOLX

HOLOGIC INC

AI score

Shared smart-money ownership · 3 shared holders

KRYGER CAPITAL Ltd CIBRA Capital Ltd Point72 Europe (London) LLP

UDMY

Udemy, Inc.

AI score

Shared smart-money ownership · 1 shared holders

KRYGER CAPITAL Ltd

OneStream, Inc.

AI score

Shared smart-money ownership · 1 shared holders

CIBRA Capital Ltd

IRTC

iRhythm Holdings, Inc.

AI score

Similar quality profile · 1 shared holders

Point72 Europe (London) LLP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FOLD on your watchlist

Track score changes the day AMICUS THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FOLD a good stock to buy?

13F Pro's AI-powered analysis of AMICUS THERAPEUTICS, INC. (FOLD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FOLD are available on the FOLD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FOLD is classified as a mid company.

Which hedge funds own FOLD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FOLD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AMICUS THERAPEUTICS, INC.'s investment landscape.